Quantum-Si Reports Second Quarter 2026 Financial Results and Provides Proteus Development Update Life Science Investing
ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results Life Science Investing
Radoff-JEC Group Calls on Seer, Inc.'s Board of Directors to Publicly Acknowledge That the Company Needs to Be Taken Private and Disclose Timeline for Evaluating Latest Acquisition Offers Life Science Investing
Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Life Science Investing
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia in Eosinophilic Esophagitis Patients Life Science Investing
Cizzle Brands Corporation Announces that CWENCH Hydration has been Named as the Official Hydration Drink of Leading Esports Organization, Luminosity Gaming Biotech Investing
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury Life Science Investing
Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Life Science Investing
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants Life Science Investing
Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million Life Science Investing
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update Life Science Investing
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026Â
